Irinotecan Hydrochloride Amarox

Irinotecan Hydrochloride, the active ingredient in Irinotecan Hydrochloride Amarox, is a topoisomerase I inhibitor presented as a sterile intravenous solution for intravenous use. It is employed in the treatment of metastatic and advanced colorectal cancer in adult patients. The drug is administered under the supervision of oncologists as part of combination chemotherapy regimens.

GNH USA supplies Irinotecan Hydrochloride Amarox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. Our distribution network ensures compliance with regulatory standards across the European Union and other global markets.

Irinotecan Hydrochloride is used in the management of colorectal cancer, a disease characterized by malignant growth of the colon or rectum.

Metastatic colorectal cancer: improves overall survival when used in combination chemotherapy regimens. Advanced colorectal cancer: reduces tumor progression and may extend progression‑free survival. Colorectal cancer (first‑line setting): contributes to disease control as part of standard treatment protocols.

Irinotecan Hydrochloride may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Diarrhea: often severe and may require medical management. - Nausea and vomiting: typical gastrointestinal symptoms. - Neutropenia: reduced white blood cell count increasing infection risk. - Fatigue: generalized tiredness affecting daily activities.

Serious or Rare Side Effects: - Severe neutropenic infection (febrile neutropenia): can be life‑threatening. - Severe diarrhea leading to dehydration and electrolyte imbalance. - Liver toxicity (elevated transaminases) or hepatic failure.

When using Irinotecan Hydrochloride, several precautions should be observed to minimize risks and ensure safe administration.

- Monitor blood counts: perform regular complete blood count tests to detect neutropenia. - Assess liver function: evaluate hepatic enzymes before and during therapy. - Hydration status: maintain adequate fluid intake to reduce severity of diarrhea. - Concomitant medications: review for drugs that may increase toxicity, such as CYP3A4 inhibitors. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks to fetus or infant. - Store at ambient temperature: keep the solution below 25 °C, protect from light, and retain in original packaging.

Irinotecan Hydrochloride can interact with other medicines, affecting its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase irinotecan plasma levels and toxicity. - UGT1A1 inhibitors (e.g., atazanavir): can raise active metabolite SN‑38, heightening risk of severe neutropenia and diarrhea. - Anticoagulants (e.g., warfarin): increased bleeding risk due to potential platelet suppression.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce drug exposure, lowering effectiveness. - Other myelosuppressive agents (e.g., carboplatin): require close monitoring of blood counts. - Antidiarrheal agents (e.g., loperamide) used for symptom control: monitor for constipation and bowel obstruction.